Artrex

Quick links to important sections

Artrex

Treatment option:

Medically reviewed

Marina Burgos

Last updated on 22/12/2025

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Artrex

What is Artrex? (Allopurinol, Colchicine)

Property Description
Active Ingredients Allopurinol, Colchicine
Form Oral tablet
Pharmacological Class Anti-gout agent; Xanthine Oxidase Inhibitor and Anti-inflammatory Agent
Common Use Management of hyperuricemia and gouty arthritis
Origin Synthetic compound (Allopurinol) and plant-derived alkaloid (Colchicine)

What Type of Medicine is Artrex (Allopurinol, Colchicine)?

Artrex is a prescription medicine and a strategic combination product classified as an anti-gout agent. It is formulated with two distinct active ingredients: Allopurinol and Colchicine. This formulation represents a medically recognized approach, combining long-term prophylactic management with acute anti-inflammatory support. The use of this dual strategy is often implemented when patients require management of elevated uric acid levels while also experiencing or being at risk for sudden gout flares. Unlike single-ingredient medications, Artrex integrates two complementary therapeutic classes.

Composition and Form: Ingredients and Origin

The composition of Artrex comprises Allopurinol, a synthetic compound, and Colchicine, a highly potent, naturally plant-derived alkaloid. Allopurinol is classified as a Xanthine Oxidase Inhibitor, and its primary function is to reduce the production of uric acid in the body. The sustained role of allopurinol in lowering uric acid is clinically recognized for stabilizing the underlying metabolic condition. Colchicine, derived from the Colchicum autumnale plant, acts as an Anti-inflammatory Agent. The medication is administered as an oral tablet for the oral route of administration.

The General Purpose of This Combination

The general therapeutic purpose of this dual-component medication is the sustained, comprehensive management of gouty arthritis. This combination strategy leverages Allopurinol to maintain uric acid reduction over time, which helps prevent crystal formation and encourages the dissolution of existing urate crystals. Simultaneously, the Colchicine component is included to provide targeted, specific suppression of the painful inflammatory response that these deposited crystals provoke during an acute gout flare, supporting overall disease control. The integration of both actions within a single product simplifies the treatment regimen for adults managing this chronic condition.

What side effects are possible with Artrex?

Possible Side Effects and Safety Information

The safety profile of this medicine is derived from the officially documented adverse reactions associated with its two active components, Allopurinol and Colchicine, as classified by government regulatory agencies. Side effects are officially categorized by their frequency and the system or organ they affect.


Frequency and Organ System Classifications

Adverse reactions are grouped by frequency, ranging from Very Common (occurring in 1 in 10 people or more) to Rare (occurring in less than 1 in 1,000 people). Common side effects often include gastrointestinal issues such as diarrhoea, nausea, and abdominal pain, and skin rash.

System-Organ Class (SOC) Key Adverse Reactions (Regulatory-Documented)
Gastrointestinal Disorders Diarrhoea, Nausea, Vomiting, Abdominal pain
Skin Disorders Rash, Alopecia, Severe Cutaneous Adverse Reactions (SCARs)
Blood Disorders Agranulocytosis, Aplastic Anaemia, Bone Marrow Depression
Musculoskeletal Disorders Myopathy, Rhabdomyolysis

Serious Adverse Reactions and Safety Constraints

Official labeling documents serious adverse reactions, which are rare but clinically significant. These include Severe Cutaneous Adverse Reactions (SCARs) such as Stevens-Johnson Syndrome (SJS) and Toxic Epidermal Necrolysis (TEN) associated with Allopurinol. Myelosuppression (bone marrow depression) and Rhabdomyolysis (severe muscle breakdown) are also documented concerns.

Safety constraints exist for specific populations. Patients with severe renal or hepatic impairment are identified as being at increased risk for toxicity. Furthermore, an increase in acute gout attacks is officially documented to occur during the initial phase of treatment with Allopurinol. Regulatory documents state that a rash or other signs of hypersensitivity require immediate discontinuation.

Overdose and Emergency Response

Suspected overdose of this medication requires immediate medical assessment for all patients, regardless of the presence or absence of initial symptoms. Fatal overdoses have been reported in both adults and children who have ingested the colchicine component.

Overdose toxicity typically begins with a gastrointestinal phase occurring within 2 to 24 hours of ingestion, characterized by Nausea, Vomiting, Abdominal Pain, and Diarrhea. This initial phase may be followed by a second, life-threatening phase marked by multisystem organ dysfunction developing within 24 hours to 7 days.

Severe outcomes officially documented in regulatory labels include Bone Marrow Depression (leukopenia, aplastic anemia), Cardiac Arrhythmias, Acute Renal Failure, Rhabdomyolysis, and respiratory distress leading to potential cardiovascular collapse.

There is no specific antidote available for overdose toxicity. Management is strictly based on symptomatic and supportive measures, requiring close clinical and biological monitoring in a hospital environment, including monitoring of vital signs and ECG. Patients with renal impairment, hepatic impairment, or those who are elderly and debilitated are cited in regulatory documentation as being at increased risk for toxicity.

Therapeutic Uses of Artrex

The medication is commonly used to help manage chronic gouty arthritis, a condition associated with symptoms related to systemic imbalance. A component of this treatment is used to lower high levels of uric acid associated with the underlying condition. The overall approach is used for managing the symptoms linked to organ-specific functional stress while also providing support during episodic changes.


Key Therapeutic Focus

This treatment is primarily applied across domains where sustained support is needed to address hyperuricemia (excess uric acid) and the recurrent or episodic manifestations of gout. The long-term component is relevant for managing the chronic condition, while the combination assists with managing symptoms that interfere with daily functioning, providing supportive relief. Indications commonly covered include the long-term management of hyperuricemia, supportive relief during acute symptomatic episodes, and the comprehensive strategy for recurrent or episodic manifestations.

“The approach helps maintain a sense of stability when symptoms are more noticeable.”

Supportive Relief During Acute Symptomatic Episodes

The anti-inflammatory component is commonly used to help manage symptoms related to inflammatory or irritative states, specifically those that become more disruptive during flare-ups. This support is relevant when short-term symptomatic assistance is needed. By assisting with the management of symptoms related to physical discomfort, the medication contributes to improved comfort during these periods of heightened symptoms.


Quick Fact: Relief for Physical Discomfort and Episodic Changes

Regulatory References

  1. NIH MedlinePlus Drug Information

Eligibility and Restrictions for Use

Artrex (Allopurinol, Colchicine) is officially allowed for use in adult patients managing symptomatic gout and chronic hyperuricemia. The medicine is contraindicated and must not be used by several populations. These include individuals with a prior history of severe hypersensitivity to Allopurinol or any ingredient, and patients diagnosed with pre-existing blood dyscrasias (e.g., severe bone marrow suppression) due to the Colchicine component.

Due to the excretion of active ingredients, Artrex is also absolutely contraindicated in breastfeeding women. Eligibility is limited by organ function: patients with co-morbid severe renal and hepatic impairment are typically contraindicated. Use is not recommended for the treatment of asymptomatic hyperuricemia alone.

Use in pediatric patients is severely restricted and only permitted for hyperuricemia secondary to malignancy or Lesch-Nyhan syndrome; safety for other uses is not established. Individuals with single-organ impairment (hepatic or renal) require caution and close monitoring, as use is restricted. Additionally, women who are pregnant should not use Artrex unless the potential benefit significantly outweighs the potential risk.

What should I know about interactions with other medicines?

Interactions with other medicines and products

This section summarizes the officially documented interactions for the components of Artrex, Allopurinol and Colchicine, as outlined in government regulatory information.

Category Officially Documented Interaction Basis
PK/Metabolic Interactions Allopurinol inhibits Xanthine Oxidase (XO). Colchicine is a substrate of the CYP3A4 enzyme and the P-glycoprotein (P-gp) transporter.
Pharmacodynamic Risk Increased risk of neuromuscular toxicity (e.g., myotoxicity) with co-administered lipid-regulating agents (Statins or Fibrates).

Regulatory Interaction Classifications

Contraindicated Combinations

The co-administration of the Colchicine component with Strong CYP3A4 Inhibitors (e.g., Clarithromycin) or P-gp Inhibitors is strictly contraindicated in patients with renal impairment or hepatic impairment. This combination carries an elevated risk of life-threatening toxicity.

Clinically Significant PK Interactions

  • Allopurinol significantly increases the plasma levels of Mercaptopurine and Azathioprine by inhibiting the XO enzyme pathway. Regulatory documents require a major dose reduction of these cytotoxic agents when co-administered.
  • Colchicine exposure is significantly increased by CYP3A4 and P-gp Inhibitors, which may necessitate dose adjustments or spacing if co-administration is deemed required.
  • The combination of Allopurinol with Pegloticase is formally restricted, requiring the cessation of Allopurinol during treatment.

Interaction-Related Restrictions

Consumption of Grapefruit or Grapefruit Juice is explicitly restricted due to its potential to significantly increase Colchicine plasma concentrations. Additionally, co-administration of Allopurinol with Ampicillin or Amoxicillin is associated with an officially documented increase in the frequency of skin rash.

Mechanism of Action

Modulating Purine Catabolism via Enzyme Inhibition

This core mechanism involves Allopurinol, which functions by inhibiting the enzyme Xanthine Oxidase (XO), the final catalyst in uric acid synthesis. Blocking this enzyme prevents the formation of uric acid, leading to a sustained, systemic decrease in serum urate levels. This systemic reduction initiates the reversal of the physicochemical gradient for crystal formation, which facilitates the dissolution of Monosodium Urate crystals.


Modulating Innate Immune Cell Activity through Microtubule Disruption

The second mechanism, driven by Colchicine, involves modulating the activity of innate immune cells. By binding to beta-tubulin, Colchicine disrupts microtubule assembly, impeding the migration of immune cells and inhibiting the activation of the NLRP3 Inflammasome. This interference modulates the local inflammatory signaling cascade by inhibiting the secretion of pro-inflammatory mediators like Interleukin-1beta.


Complementary Action of Metabolic and Cellular Control

The combination involves the co-application of two distinct mechanistic pathways: one that decreases the rate of uric acid synthesis and one that modulates innate immune cell activity. This dual-pathway modulation addresses both the chronic biochemical imbalance and the acute cellular response.

Dosage and Administration Information

How to Use Artrex

Artrex is administered via the oral route as an oral tablet, reflecting the standard delivery method for its dual active components. The medication's usage protocol is distinct for its two components, designed to manage chronic conditions while providing acute support.


Official Dosing and Administration Principles

Feature Official Use Instructions (Label-Aligned)
Route of Administration Oral only, involving swallowing the tablet.
Allopurinol (Urate-Lowering) Dosing The typical starting dose is 100 mg once daily or less, which is then gradually titrated to a standard maintenance range of 200 mg to 600 mg daily. The maximum recommended dose is 800 mg daily.
Colchicine (Prophylaxis) Administered at 0.6 mg once or twice daily to prevent gout flares during the initial stages of urate-lowering therapy.
Colchicine (Acute Flare) Used for a short course, beginning with 1.2 mg followed by 0.6 mg one hour later, for a total of 1.8 mg in a limited time period.

Timing and Special Procedural Constraints

The long-term urate-lowering component (Allopurinol) may be taken following meals to mitigate potential gastrointestinal discomfort, while the anti-inflammatory component (Colchicine) is administered without regard to meals. To support the urate-lowering process, increasing daily fluid intake is part of the administration protocol.

Official labels also mandate that the acute Colchicine treatment course should not be repeated more than once every two weeks. The prophylactic Colchicine component is typically co-administered for at least six months upon initiation of urate-lowering therapy. Patients with renal impairment require significant starting dose reductions for the Allopurinol component, with further adjustments based on the severity of kidney function.

Recent Clinical Evidence

Research Evidence / Overview of Studies for Artrex (Allopurinol/Colchicine)

Evidence for Prophylaxis During Urate-Lowering Therapy Initiation

This section will summarize the types of research, primarily Randomized Controlled Trials (RCTs) and Systematic Reviews, that have been conducted to evaluate the effect of the strategy on the measured rate of gout flares in adults with chronic gout.

The research exploring the combined strategy was evaluated in adults with chronic gouty arthritis, a condition characterized by fluctuating or episodic manifestations. Studies were designed as Randomized Controlled Trials and applied in research exploring how symptoms change over time, specifically during the initial phase when patients start the long-term, uric acid-lowering component (Allopurinol). Researchers sought to monitor outcomes related to episodic or acute changes—specifically, the frequency of gout flare-ups.

Studies observed patterns in the change of outcomes describing episodic or acute changes when the anti-inflammatory component was used during the initial months of Allopurinol therapy. Findings describe patterns observed in the studies related to the measured rate of acute flare-ups during this defined study period. The research also consistently monitored the background effects on serum urate levels, which is a key biomarker for the underlying systemic imbalance. Studies contribute to the broader evidence landscape.

Overview of Study Outcomes and Measured Effects

This part will describe the high-level measures examined by researchers, such as the tracking of gout flare frequency, flare severity (e.g., pain scores), and the background change in the serum urate biomarker over the study period, without stating any conclusions about the results.

Research examined how symptoms evolved in the observed populations by tracking patient-reported experiences and monitoring objective measures. Outcomes that were studied for change included flare frequency, which describes the rate of acute, disruptive episodes, and flare severity, which was often captured using scales to assess outcomes related to physical discomfort. These measurements were used to provide context on the observation of phases of heightened symptom activity.

Research in Special Populations and Chronic Conditions

This area will detail which specific patient groups were included in the regulatory research, focusing on what studies have been conducted for adults with coexisting conditions, such as chronic kidney disease, and what limitations exist for other specific populations.

The study populations were observed in adults with a diagnosis of gout. Research has explored the treatment approach in subgroups of patients with coexisting conditions, including those with chronic kidney disease (CKD). However, evidence is limited or generally unavailable for patients with severe organ impairment or other highly complex underlying conditions. The results apply only to the populations studied, and findings describing group patterns do not determine whether an individual from a different subgroup will respond similarly.

Key Studies & References

  1. 2020 American College of Rheumatology Guideline for the Management of Gout

Frequently Asked Questions (FAQ)

Common questions about Artrex (FAQ)

Q: Is Artrex the same as ibuprofen or other common pain relievers?

A: No, Artrex is not classified in the same group as common pain relievers or non-steroidal anti-inflammatory drugs (NSAIDs) like ibuprofen. Artrex is a unique combination product with two active ingredients that have different effects. One component, Allopurinol, works long-term by reducing uric acid production, while the other, Colchicine, is an anti-inflammatory agent that modulates specific cellular processes.

Q: If I miss a dose of Artrex, what should I do?

A: Regulatory instructions often describe the procedure for a missed dose: taking the dose as soon as it is remembered, unless it is nearly time for the next scheduled dose. In that case, the missed dose is typically omitted, and the regular schedule is resumed. Regulatory documents consistently describe that doubling the dose to compensate for a missed dose is not recommended.

Q: How quickly should I expect Artrex to start working?

A: The medication's two components work on different timelines. The anti-inflammatory component (Colchicine) is used for acute purposes and is typically applied at the first signs of a flare. In contrast, the urate-lowering component (Allopurinol) is a long-term treatment designed to reduce uric acid levels gradually, a process that may require continuous use over several weeks or months to reach full effectiveness.

Q: Are there any specific foods or drinks to avoid while taking Artrex?

A: Yes, official regulatory documents strictly advise avoiding Grapefruit and Grapefruit Juice. Official labeling advises against this combination due to the potential for a significant increase in the Colchicine component's concentration in the body. Beyond grapefruit, other specific food or drink restrictions are not generally listed in official labeling.

Q: Is Artrex known to cause drowsiness or affect driving?

A: Drowsiness is not typically listed as a common or frequent side effect during treatment with Artrex. However, symptoms such as dizziness or light-headedness are documented in official safety information as signs of potential toxicity. The potential for these symptoms suggests that the ability to drive or operate machinery should be considered while using the medication.

Q: How long can a person safely take Artrex continuously?

A: The duration depends on the treatment goal of each component. The urate-lowering component (Allopurinol) is often intended for long-term or continuous management to keep uric acid levels stable. The anti-inflammatory component (Colchicine) is used for a defined, limited period for flare prevention, such as during the first few months of urate-lowering therapy.

Q: Can older adults use Artrex safely?

A: Use in older adults requires specific caution. Official documents note that elderly patients, even those without pre-existing organ problems, have an increased, documented risk of developing neuromuscular toxicity (muscle and nerve issues) from the Colchicine component. This increased risk is a factor considered when treatment is administered.

Q: Is Artrex safe to use if I have kidney problems?

A: The use of Artrex requires careful consideration for individuals with kidney problems. While severe renal impairment is listed as a contraindication, regulatory documents indicate that patients with mild-to-moderate kidney impairment may still be eligible for treatment. For these cases, regulatory documents indicate the need for dose adjustments and close, regular monitoring of kidney function.

Q: What is the difference between Artrex and medication X (a competitor)?

A: Artrex is defined by its unique composition, which is a fixed combination of two distinct active drugs: Allopurinol and Colchicine. This dual formulation targets both the long-term metabolic imbalance (uric acid reduction) and the acute inflammatory response simultaneously. Other medicines may contain only one of these components or use an entirely different pharmacological approach to manage gout.

Q: Can Artrex be used by people with diabetes?

A: Regulatory documents list certain coexisting conditions, including diabetes and high blood pressure, as requiring caution and close monitoring during the use of the Allopurinol component. Diabetes itself is not listed as an absolute contraindication for the medication. The use of Artrex with any pre-existing condition requires close medical guidance.

Q: Is Artrex a habit-forming drug?

A: No. The active components of the medication, Allopurinol and Colchicine, are not classified as controlled substances. Official regulatory schedules do not list Artrex as having abuse potential or being a habit-forming drug.

Q: What happens if Artrex is stopped suddenly?

A: Official warnings note that the sudden discontinuation of the urate-lowering component (Allopurinol) is associated with an increased risk of worsening gout or the occurrence of an acute flare-up. Any changes to the treatment plan are managed under the guidance of a healthcare professional.

Q: Does Artrex interact with oral contraceptives or hormone replacement therapy?

A: Official regulatory documents do not typically highlight a specific major interaction between Artrex and hormonal products like oral contraceptives or hormone replacement therapy. However, because one component of Artrex (Colchicine) is metabolized through a common enzyme pathway, consulting a healthcare professional about all hormonal products is required.

Q: Are there any long-term health concerns associated with Artrex use?

A: Official documents describe certain potential risks associated with the chronic use of the Colchicine component. These documented concerns include rare instances of neuromuscular toxicity (muscle and nerve issues) and bone marrow suppression (myelosuppression), which is why ongoing monitoring is required during long-term therapy.

Q: Is it true that Artrex might affect fertility?

A: Official safety information documents that the Colchicine component may potentially have an effect on sperm count in men. This effect is often described as reversible once the medication is stopped. Any concerns regarding fertility are managed by a healthcare professional.

Q: Can Artrex be crushed or split if it's hard to swallow?

A: The Artrex tablet is intended to be swallowed whole. Regulatory guidance advises against altering the form of the tablet, as crushing or splitting it may affect the way the two different components are absorbed or released in the body.

Q: Is Artrex considered a first-line treatment for the conditions it treats?

A: Both active components are generally recognized as key management options for gout. The Allopurinol component is a recognized first-line therapy for the long-term lowering of uric acid. The Colchicine component is also a first-line agent used for treating or preventing acute gout flares.

Q: Are there different strengths of Artrex available?

A: Yes. The medicine is manufactured in specific, fixed combinations of its two active ingredients. The dosage section of the official label details the exact pre-set strengths of the Allopurinol and Colchicine components that are available in the product.

Q: Is Artrex known to cause skin rashes or sensitivity to the sun?

A: A skin rash is officially listed as a common side effect associated with the Allopurinol component. However, official regulatory safety documents do not list photosensitivity (severe sensitivity to the sun) as a key or frequent documented adverse reaction.

Q: How do researchers describe the long-term safety profile of Artrex?

A: Researchers continuously monitor the long-term safety profile of the medication. Studies focus on the rare, but documented, risks of myopathy, neuromuscular toxicity, and hematological issues associated with chronic use of the anti-inflammatory component, ensuring that ongoing safety data is collected and analyzed.

Q: Can Artrex be taken with acetaminophen (Tylenol)?

A: Regulatory information concerning the Allopurinol component generally indicates that no major interaction is expected when it is used with acetaminophen (Tylenol). The use of any combined medications is managed under the consultation of a healthcare professional.

Q: How soon after stopping Artrex can I drink alcohol?

A: Official guidance does not typically specify a waiting period for alcohol consumption after stopping the medication. Patients should be aware that consuming alcohol can itself lead to an increase in uric acid levels, potentially worsening the underlying gout condition.

Q: Does Artrex affect blood pressure or heart rate?

A: Changes in blood pressure or heart rate are not listed as common side effects of Artrex in official safety documents. However, signs of low blood pressure are documented in regulatory sources as a symptom of potential toxicity or overdose of the Colchicine component.

Q: Does taking Artrex require any special monitoring or blood tests?

A: Yes, official regulatory use requires ongoing monitoring. This typically includes blood tests to track the reduction in serum urate levels and to periodically check kidney function. Additional monitoring of blood cell counts may be necessary due to the rare, documented risk of blood disorders.

How should Artrex be stored and disposed of?

Storage Requirements

Artrex (allopurinol/colchicine) tablets must be stored at Controlled Room Temperature, specifically 20 C to 25 C (68 F to 77 F). The medication must be kept from freezing and away from excessive heat. To maintain stability, the tablets must be stored in their original container, which should be kept tightly closed and protected from both light and moisture. The official labeling mandates that the medicine must be stored out of the reach of children.


Disposal Protocol

Regulatory guidance instructs patients not to keep outdated or unused medicine. Disposal of leftover tablets should be handled safely. Patients are directed to consult with a healthcare professional or pharmacist regarding the correct method to discard any unused product, ensuring compliance with local requirements.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

Equivalent of Artrex found in:

A-Z Index: